You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》花旗對中資醫療板塊最新投資評級及目標價(表)
阿思達克 09-15 15:32
花旗發表研究報告,對中資醫療板塊最新投資評級及目標價表列如下:

股份|投資評級|目標價(港元)

藥廠

翰森製藥(03692.HK)|買入|50元

中生製藥(01177.HK)|買入|12.8元

石藥集團(01093.HK)|買入|18.2元

復星醫藥(02196.HK)|買入|37.8元

李氏大藥廠(00950.HK)|買入|7元

綠葉製藥(02186.HK)|中性|4.7元

生物科技

亞盛醫藥(06855.HK)|買入|60元

三生製藥(01530.HK)|中性|11元

君實生物(01877.HK)|買入|80元

復宏漢霖(02696.HK)|買入|66元

互聯網健康

阿里健康(00241.HK)|買入|30元

平安好醫生(01833.HK)|買入|150元

保健服務

華潤醫療(01515.HK) |中性|5.6元

康寧醫院(02120.HK) |買入|30元

分銷商

國藥控股(01099.HK)|買入|28元

康哲藥業(00867.HK)|中性|11.1元

上海醫藥(02607.HK)|買入|18元

傳統中藥

白雲山(00874.HK)|中性|26.5元

同仁堂科技(01666.HK)|買入|7.5元

醫療器材

昊海生物科技(06826.HK)|買入|100元

威高股份(01066.HK)|中性|18元

錦欣生殖(01951.HK)|買入|16元

微創醫療(00853.HK)|中性|35元

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account